EU EPPerMed consortium PGxMTB

The PGxMTB framework integrates germline and somatic multiomics to systematically extract pharmacogenomic (PGx) and drug target information. This enables enhanced therapeutic decision-making in MTBs and extends the scope of traditional precision oncology workflows. Health economic evaluations will assess the impact of PGx implementation across healthcare systems. Innovative analyses of liver-derived extracellular vesicles will characterise tumour-related changes in individual liver PGx phenotypes. Patient representatives are involved as research partners throughout the project.

Coordinator: Matthias Schwab, MD - Head of the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology